Regarding the role of CXCR4 in TLR7-mediated inflammation and promising results following treatment of TLR7-dependent lupus-like model with IT1t (a CXCR4 inhibitor), it is possible that administrating Clobenpropit reduces systemic inflammation by suppressing type I IFNs production by pDCs and anti-dsDNA autoantibodies, preventing glomerulonephritis in SLE (Smith et al., 2019) (Table 1). The gene discussed is TLR7; the disease is systemic lupus erythematosus.